Estimates and predictors of health care costs of esophageal adenocarcinoma: a population-based cohort study

Abstract

[...]EAC has become the predominant histological subtype of esophageal cancer (relative to squamous cell carcinoma) in North America and Europe, and the sixth leading cause of cancer-related deaths worldwide [1, 7, 8]. [...]lower costs were associated with individuals diagnosed with EAC included 85 years of age and older at index date and rural residence in the initial phase. According to a large randomized trial, preoperative chemoradiotherapy is safe and leads to a significant increase in overall survival among patients with localized adenocarcinoma or squamous-cell carcinoma of the esophagus compared with those treated with surgery alone [61]. Because Ontario only provides comprehensive coverage for the elderly and those on social assistance, prescription medication costs were not included for patients < 65 years.